These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

726 related items for PubMed ID: 8650968

  • 1. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
    Nauck MA, Siemsglüss J, Orskov C, Holst JJ.
    Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
    [Abstract] [Full Text] [Related]

  • 2. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [Abstract] [Full Text] [Related]

  • 3. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
    Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA.
    Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
    [Abstract] [Full Text] [Related]

  • 4. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ.
    Regul Pept; 2004 Nov 15; 122(3):209-17. PubMed ID: 15491793
    [Abstract] [Full Text] [Related]

  • 5. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
    Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK.
    Am J Physiol Endocrinol Metab; 2011 Jun 15; 300(6):E1038-46. PubMed ID: 21386059
    [Abstract] [Full Text] [Related]

  • 6. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.
    J Clin Endocrinol Metab; 2003 Oct 15; 88(10):4897-903. PubMed ID: 14557471
    [Abstract] [Full Text] [Related]

  • 7. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM.
    Am J Physiol Endocrinol Metab; 2006 Mar 15; 290(3):E550-9. PubMed ID: 16219666
    [Abstract] [Full Text] [Related]

  • 8. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection.
    Bendet N, Scapa E, Cohen O, Bloch O, Aharoni D, Ramot Y, Weiss M, Halevi A, Rapoport MJ.
    Scand J Gastroenterol; 2004 Jul 15; 39(7):650-6. PubMed ID: 15370686
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.
    J Clin Invest; 1993 Jan 15; 91(1):301-7. PubMed ID: 8423228
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O, Haugaard SB, Holst JJ, Deacon CF, Iversen J, Andersen UB, Nielsen JO, Madsbad S.
    HIV Med; 2005 Mar 15; 6(2):91-8. PubMed ID: 15807714
    [Abstract] [Full Text] [Related]

  • 14. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
    Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB.
    Eur J Endocrinol; 1996 Oct 15; 135(4):425-32. PubMed ID: 8921824
    [Abstract] [Full Text] [Related]

  • 15. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Diabetologia; 2002 Aug 15; 45(8):1111-9. PubMed ID: 12189441
    [Abstract] [Full Text] [Related]

  • 16. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
    Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B.
    Diabetes; 2004 Mar 15; 53(3):654-62. PubMed ID: 14988249
    [Abstract] [Full Text] [Related]

  • 17. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
    Chaikomin R, Doran S, Jones KL, Feinle-Bisset C, O'Donovan D, Rayner CK, Horowitz M.
    Am J Physiol Endocrinol Metab; 2005 Sep 15; 289(3):E504-7. PubMed ID: 15886226
    [Abstract] [Full Text] [Related]

  • 18. GLP-1 release in man after lower large bowel resection or intrarectal glucose administration.
    Printz H, Reiter S, Samadi N, Ebrahimsade S, Kirchner R, Arnold R, Göke B.
    Digestion; 1998 Sep 15; 59(6):689-95. PubMed ID: 9813395
    [Abstract] [Full Text] [Related]

  • 19. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ.
    Diabetes; 2008 Mar 15; 57(3):678-87. PubMed ID: 18057091
    [Abstract] [Full Text] [Related]

  • 20. Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis.
    Calanna S, Piro S, Di Pino A, Maria Zagami R, Urbano F, Purrello F, Maria Rabuazzo A.
    Obesity (Silver Spring); 2013 Feb 15; 21(2):320-5. PubMed ID: 23404781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.